AZD 2820

Drug Profile

AZD 2820

Alternative Names: AZD-2820

Latest Information Update: 13 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca; Palatin Technologies
  • Developer AstraZeneca
  • Class Obesity therapies; Peptides
  • Mechanism of Action Melanocortin type 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 29 Sep 2015 Palatin terminates its research collaboration and license agreement with AstraZeneca for melanocortin 4 receptor agonists in USA
  • 07 Sep 2012 Discontinued - Phase-I for Obesity in United Kingdom (SC)
  • 20 Jun 2012 AstraZeneca terminates phase I trial in Obesity in UK (NCT01469923)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top